GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.295
-0.007 (-2.19%)
At close: Feb 21, 2025, 4:00 PM
0.287
-0.008 (-2.61%)
After-hours: Feb 21, 2025, 7:58 PM EST
GlycoMimetics Employees
GlycoMimetics had 35 employees as of December 31, 2023. The number of employees decreased by 4 or -10.26% compared to the previous year.
Employees
35
Change (1Y)
-4
Growth (1Y)
-10.26%
Revenue / Employee
n/a
Profits / Employee
-$1,082,262
Market Cap
19.03M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
GLYC News
- 3 months ago - Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - PRNewsWire
- 3 months ago - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
- 4 months ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 4 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 4 months ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
- 4 months ago - GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire
- 7 months ago - GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Business Wire
- 9 months ago - GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire